1. Home
  2. PRTA vs SES Comparison

PRTA vs SES Comparison

Compare PRTA & SES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.03

Market Cap

449.7M

Sector

Health Care

ML Signal

N/A

Logo SES AI Corporation

SES

SES AI Corporation

N/A

Current Price

$0.51

Market Cap

384.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
PRTA
SES
Founded
2012
2012
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
449.7M
384.1M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
PRTA
SES
Price
$9.03
$0.51
Analyst Decision
Buy
Buy
Analyst Count
9
1
Target Price
$19.00
$4.00
AVG Volume (30 Days)
471.8K
18.2M
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.03
EPS
0.26
N/A
Revenue
$814,000.00
$21,000,000.00
Revenue This Year
$1,111.38
$53.90
Revenue Next Year
N/A
$111.26
P/E Ratio
$35.73
N/A
Revenue Growth
N/A
929.41
52 Week Low
$7.73
$0.49
52 Week High
$11.80
$3.73

Technical Indicators

Market Signals
Indicator
PRTA
SES
Relative Strength Index (RSI) 51.70 37.49
Support Level $8.91 $0.49
Resistance Level $9.36 $0.67
Average True Range (ATR) 0.41 0.06
MACD 0.05 0.01
Stochastic Oscillator 70.19 5.14

Price Performance

Historical Comparison
PRTA
SES

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About SES SES AI Corporation

SES AI Corp is a developer and manufacturer of rechargeable battery technologies and battery materials for Energy Storage Systems (ESS), Urban Air Mobility (UAM), drones, robotics, electric vehicles (EVs), and other applications. For Enery Storage Systems, the company supplies hardware and software solutions with battery health and safety management software powered by its AI-based platform, Molecular Universe. Additionally, it offers battery materials and high-energy and power-density Li-Metal and Li-ion cells, which can be used for drones, UAM, robotics, and EV applications. The company also offers access to Molecular Universe as a software product. Currently, it generates maximum revenue from the development of Li-ion and Li-Metal battery materials as per the client's specifications.

Share on Social Networks: